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Hannah Smith RN, BSN, CCRN
Introduction
The topic to be discussed is von Willebrand disease.  Von 
Willebrand disease is named after the scientist that discovered 
the disorder; Erik von Willebrand. von Willebrand disease (VWB) 
is one of the many types of bleeding disorders (Leebeek & 
Eikenboom, 2016, p. 2067).  The disease is an autosomal 
inherited mutation and is the most common of the bleeding 
disorders.  Von Willebrand factor’s main functions are to bind to 
collagen sites during vascular injury, play a role in platelet 
adhesion and aggregation, and is a carrier protein for factor VIII.  
When von Willebrand factor is missing, depleted or 
malfunctioning symptoms of pathological bleeding occur.  VWD 
varies in how the altered gene is expressed phenotypically.  The 
disease is subdivided into categories based on severity and 
alteration of the Von Willebrand factor.  Part of the range in 
symptoms and severity is in part because VWD can be a 
dominant or recessive inheritance pattern (Leebeek & 
Eikenboom, 2016, p. 2068).  There is an array of VWD screening 
tests and confirmatory tests that would need to be done to not 
only diagnose VWD but also to determine which category, and 
therefore, severity the patient has (Roberts & Flood, 2015).
This topic was chosen because this disease becomes a 
complication for patients who need surgery or are victims of 
trauma.  The author is currently working in the post-anesthesia 
care unit at Grant Medical Center, which is also a level 1 trauma 
center.  Special consideration needs to be given to this 
vulnerable population.  Knowledge of this disease will also be 
helpful in any type of future practice setting.
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Underlying Pathophysiology
• Inheritance patterns: The subtypes are VWD 1, VWD2A, VWD2B, VWD2M, VWD2N and VWD 3.  VWD 1 is 
the mildest and VWD 3 is the most severe.  VWD 1, VWD2B, VWD2M are an autosomal dominant 
inheritance pattern.  VWD2N and VWD 3 are a recessive inheritance pattern and VWD2A can be both 
(Federici, 2016, p. 42).  Type 3 VWD contains null alleles which results in the complete nonappearance on 
von Willebrand factor. Type 1 VWD has incomplete penetrance and involves defects in intracellular 
routing, storage, secretion and faster clearance of von Willebrand factor.  Type 2 is fully penetrant and 
results in restriction of the von Willebrand factor protein (Leebeek & Eikenboom, 2016, p. 2071).
• Normal von Willebrand function: von Willebrand factor (VWF) is synthesized in the endothelial cells and is 
either secreted or stored within the endothelial cells where they are kept until they are stimulated.  VWF 
contains amino acids that play a role in the structure or function of the molecule.  VWF is made 
specifically in the endoplasmic reticulum of the cell where it becomes a large high molecular weight 
multimer that binds collagen and contains the platelet receptors GPIb and GPII/IIIa (Schneppenheim, 
2011, p. 53-54).
• Subtype pathophysiology:  The subtypes are classified as such do to their mechanism of action.  VWD 1, 
the mildest form, has less than the normal amount of von Willebrand factor.  VWD2A has decreased 
platelet adhesion.  VWD2A loses its platelet adhesion because it loses its multimer shape and is no longer 
of high molecular weight.  VWD2B has increased affinity for the platelet GPIb alpha.  VWD2N decreases 
binding for factor VIII.  Factor VIII is a protein that plays a role in the clotting cascade.  Finally, VWD 3, the 
most severe, is complete loss of any VWF (Federici, 2016, table 1).
Signs and Symptoms
• Hemophilic arthropathy: Most common joint affected 
is the knee leading to the need for a total knee 
arthroplasty.  Chronic synovial inflammation and 
hemarthroses damage articular cartilage and cause 
severe arthritis even at a young age (Cancienne, 
Werner, & Browne, 2015, p. 2285).
• Heavy menstrual bleeding: Heavy menstrual bleeding 
(menorrhagia), especially during anovulation, 
menarche, and perimenopause.  It is recommended 
that females age 10-17 that present with heavy 
menstrual bleeding be screened for VWD and other 
bleeding disorders (Khamees, Kima, & O’Brien, 2014, p. 
195).
• Epistaxis and other mucosal bleeding (Abshire et al., 
2015, p. 1585).
• Gastrointestinal bleeding/hemorrhage (Abshire et al., 
2015, p. 1585).
• Excessive bleeding after surgery, trauma or childbirth: 
Hematomas and bleeding from minor wounds.  
Bleeding after dental extractions (Leebeek & 
Eikenboom, 2016, p. 2067).
Significance of Pathophysiology 
• Because there are so many subtypes treatment is not a one-size-fits-all problem to solve.  The patient may 
present with vague bleeding symptoms or be in critical condition due to hypovolemic shock.  Therefore, the 
caregiver must rule out and screen for any patient that increased bleeding is a part of the symptomology 
(Khamees et al., 2014). 
• Von Willebrand disease seams to affect women more than men because of monthly menstrual bleeding.  It is 
common for women to go undiagnosed and untreated.  It is a goal of Healthy People 2020 to correct this 
problem.  Therefore, women who present with heavy menstrual bleeding (hospitalization for menstrual 
bleeding, iron deficiency anemia or requiring a blood transfusion) be screened for VWD and receive treatment 
within a year of first bleeding episode (Khamees et al., 2014, p. 195-197).
• VWD has many different inheritance patterns.  Type 3 (the most severe) usually happens when the gene is 
passed from the mother as well as the father.  If the inheritance pattern is recessive, and neither parent 
phenotypically has the disease, then the child has a 25% chance on inheriting the severe form ("How von 
Willebrand is inherited," 2014, para. 1).  Therefore, information about familial genetics is vital information for 
the caregiver.
Implications for nursing care
• When a patient presents with the signs and symptoms of von 
Willebrand disease the nurse practitioner should begin with a 
detailed history, especially a familial health history, and a 
physical exam.  Preliminary laboratory tests include a platelet 
count, thyroid level, prothrombin time, activated partial 
thromboplastin time and a hemoglobin and hematocrit level 
(Brooks, Brooks, & Alvaro, 2016, p. 102).
• If these results come back as abnormal, if there is a familial 
history of bleeding disorders or any of the severe bleeding signs 
are present (see above) the patient should be screened for a 
bleeding disorder.  VWD screening tests include VWF antigen 
(VWF:Ag), VWF ristocetin cofactor activity (VWF:RCo), factor VIII 
activity (FVIII:Cand VWF:RCo/VWF:Ag (Roberts & Flood, 2015, p. 
12-13).
• Once a definitive diagnosis for VWD has been made the nurse 
practitioner should refer the patient to a hematologist.  From 
there, treatment varies depending on the subtype of VWD the 
patient has.  After the patient has received initial appropriate 
treatment and is stable the nurse practitioner can resume care of 
the patient to perform routine laboratory work and prescribe of 
medication (Brooks et al., 2016, p. 104).
• Type 1 VWD (and sometimes type 2) is commonly treated with 
desmopressin acetate (DDAVP).  The use of this drug increases 
factor VIII and of VWF.  The drug causes temporary 
vasoconstriction which elicits the endothelial cells to release 
clotting factors (Kauffman, 2014, p. 91).
• In type 3 and in the majority of type 2 patients factor 
replacement is necessary (Leebeek & Eikenboom, 2016, p. 2075-
2076).
• Tranexamic acid and aminocaproic acid are fibrinolysis inhibitors 
can be given in a mouthwash form prophylactically to patients 
undergoing dental procedures (Leebeek & Eikenboom, 2016, p. 
2077).
• Anti-platelets may be given to individuals with type 2B VWD due 
to the mutated GP-Ib-IX platelet receptor.  The mutated receptor 
has a dysfunctional affinity for platelets making the VWF “tied 
up” with the platelets rather than being able to aid in the clot 
formation of a real vascular injury (Ware, 2013, p. 5004).
• Oral contraceptives can be given to women with symptoms of 
heavy menstrual cycles but special care must be taken as to not 
mask the symptoms before getting a definitive von Willebrand 
disease diagnoses (Brooks et al., 2016, p. 104).
• The nurse practitioner should be aware that the patient will have 
a higher risk for infection, medical complications, venous 
thromboembolism and blood transfusions following trauma or 
surgical procedures (Cancienne et al., 2015, p. 2286).
• Lastly the patient must be educated about the disease, new 
medications, how to care for oneself and given information 
about support groups, community resources and genetic 
counseling (Brooks et al., 2016, p. 102).
Conclusion
• Von Willebrand factor’s function is to bind to 
collagen sites during vascular injury, play a role in 
platelet adhesion and aggregation, and is a carrier 
protein for factor VIII.  Malfunction of this factor 
can cause bleeding symptoms. (Leebeek & 
Eikenboom, 2016).
• VWD can be inherited either autosomal dominant 
or recessive.  ("How von Willebrand is inherited," 
2014).  The types and subtypes are determined by 
inheritance pattern and underlying 
pathophysiology.  The mildest (type 1) is caused 
by insufficient VWF and the most severe (type 3) 
is complete absence of VWF (Federici, 2016).
• Diagnoses is made from a wide range of 
laboratory results that each type (and subtype) 
follow (Roberts & Flood, 2015).
• Treatment also varies based on the type of VWD 
diagnosed.  DDAVP, anti-platelets and intravenous 
administered factor are all options. Despite 
treatment patients are at higher risk for infection 
and other complications following surgery or 
trauma (Leebeek & Eikenboom, 2016).
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